【中文品名】阿莫曲坦
【药效类别】抗偏头痛药
【通用药名】ALMOTRIPTAN
【别　　名】Axert, Almogran
【化学名称】 βα
【CA登记号】[154323-57-6]
【结 构 式】

【分 子 式】CHNOPS·
【分 子 量】
【收录药典】
【开发单位】Almirall-Prodesfarma
【首次上市】2000年，西班牙
【性　　状】
【用　　途】
用于有或无先兆的偏头痛发作的头痛期急性治疗。

生产厂家: Janssen-Ortho

阿莫曲坦（almotriptan,Axert），适用于有无先兆的急性偏头痛成人患者。本品通常耐受性良好，多数副作用轻微。
有6 .25 mg和12.5 mg两种规格的片剂。
阿莫曲坦（almotriptan），对颅内血管5-HT 1B/1D 受体有高度选择性，对冠状动脉的致痉作用较其他曲坦类药物小，对脑动脉的作用比舒马曲坦强25倍。口服给药有效率为66%～88%，皮下给药有效率超过90% .

２００９年６月３日，Ａｌｍｉｒａｌｌ公司宣称美国食品和药物管理局已经批准Ａｘｅｒｔ（阿莫曲普坦）治疗青少年（１２～１７岁）急性偏头痛。曾经在２００１年被ＦＤＡ批准用于治疗成人偏头痛，Ａｘｅｒｔ是最早被ＦＤＡ批准用于治疗青少年偏头痛的药物。为它给青少年带来了福音。

Axert is a medication used to treat migraine attacks in adults. Axert belongs to a class of drugs called selective serotonin receptor agonists. Axert reduces the swelling of blood vessels that surround your brain. This swelling is associated with the headache pain of a migraine attack. Axert blocks the release of substances from nerve endings that cause more pain and other migraine symptoms, and it also interrupts the pain signals that are sent your brain. By doing all of these things, Axert helps to relieve the symptoms of your migraine.

INDICATIONS
Acute Treatment of Migraine Attacks
Adults: AXERT (almotriptan malate) is indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura.
Adolescents age 12 to 17 years: AXERT is indicated for the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated).
Important Limitations
AXERT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with AXERT, the diagnosis of migraine should be reconsidered before AXERT is administered to treat any subsequent attacks.
In adolescents age 12-17 years, efficacy of AXERT on migraine associated symptoms (nausea, photophobia and phonophobia) was not established. AXERT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine [see CONTRAINDICATIONS].
Safety and effectiveness of AXERT have not been established for cluster headache which is present in an older, predominantly male population.
DOSAGE AND ADMINISTRATION
Acute Treatment of Migraine Attacks
The recommended dose of AXERT in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of AXERT, the choice of dose should be made on an individual basis.
If the headache is relieved after the initial AXERT dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.
Hepatic Impairment
The recommended starting dose of AXERT in patients with hepatic impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].
Renal Impairment
The recommended starting dose of AXERT in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period [see WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY].
HOW SUPPLIED
Dosage Forms And Strengths
AXERT (almotriptan malate) Tablets are available as white, coated, circular, biconvex tablets in the following dosage strengths:
6.25 mg tablet with red code imprint “2080”
12.5 mg tablet with blue stylized imprint “A.”
AXERT® (almotriptan malate) Tablets are available as follows:
6.25 mg: White, coated, circular, biconvex tablets with red code imprint “2080.”
Unit Dose (aluminum blister pack)
6 tablets.............NDC 0062-2080-06
12.5 mg: White, coated, circular, biconvex tablets with blue stylized imprint “A.”
Unit Dose (aluminum blister pack)
12 tablets.............NDC 0062-2085-12
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled room temperature].
AXERT Tablets are manufactured by: Janssen-Ortho, LLC Gurabo, Puerto Rico 00778. AXERT Tablets are manufactured for: Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Raritan, NJ 08869. Licensed from: Laboratorios Almirall, S.A.